Details of the Drug

General Information of Drug (ID: DMGB5RE)

Drug Name
Tranylcypromine
Synonyms
GJZ; Jatrosom; Parnate; Parnitene; Tranilcipromina; Transamine; Tranylcyprominum; Allphar Brand of Tranylcypromine Sulfate; Esparma Brand of Tranylcypromine Sulfate; GlaxoSmithKline Brand of Tranylcypromine Sulfate; Goldshield Brand of Tranylcypromine Sulfate; Link Brand of Tranylcypromine Sulfate; Racemic Tranylcypromine; SmithKline Brand of Tranylcypromine Sulfate; SKF 385; Trans 2 Phenylcyclopropylamine; D-Tranylcypromine; Dl-Tranylcypromine; Jatrosom (TN); L-Tranylcypromine; Parmodalin (TN); Parnate (TN); Parstelin (TN); SKF Trans-385; Sicoton (TN); Sulfate, Tranylcypromine; Tranilcipromina [INN-Spanish]; Transamine (TN); Transapin (TN); Tranylcypromine (INN); Tranylcypromine [INN:BAN]; Tranylcyprominum [INN-Latin]; Tylciprine (TN); Trans-2-Phenylcyclopropylamine; Trans-DL-2-Phenylcyclopropylamine; Trans-(-)-2-Phenylcyclopropanamine; Cyclopropanamine, 2-phenyl-, (1R-trans)-(9CI); (+)-(R)-Tranylcypromine; (+)-Tranylcypromine; (+)-trans-2-Phenylcyclopropylamine; (-)-Tranylcypromine; (1R)-2-phenylcyclopropan-1-amine; (1R,2R)-2-phenylcyclopropan-1-amine; (1R,2S)-2-phenylcyclopropan-1-amine; (1R,2S)-2-phenylcyclopropanamine; (1S)-2-phenylcyclopropan-1-amine; (1S,2R)-2-phenylcyclopropan-1-amine; (1S,2S)-2-phenylcyclopropan-1-amine; (2S)-2-phenylcyclopropan-1-amine; 2-Phenylcyclopropanamine; 2-phenylcyclopropan-1-amine
Indication
Disease Entry ICD 11 Status REF
Major depressive disorder 6A70.3 Approved [1]
Prostate cancer 2C82.0 Patented [2]
Therapeutic Class
Antidepressants
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 133.19
Topological Polar Surface Area (xlogp) 1.5
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 1
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 1.5 - 3.2 hours [4]
Metabolism
The drug is metabolized via the hepatic [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 6.44 micromolar/kg/day [6]
Vd
The volume of distribution (Vd) of drug is 1.1-5.7 L/kg [7]
Water Solubility
The ability of drug to dissolve in water is measured as 48 mg/mL [3]
Chemical Identifiers
Formula
C9H11N
IUPAC Name
(1R,2S)-2-phenylcyclopropan-1-amine
Canonical SMILES
C1[C@H]([C@@H]1N)C2=CC=CC=C2
InChI
InChI=1S/C9H11N/c10-9-6-8(9)7-4-2-1-3-5-7/h1-5,8-9H,6,10H2/t8-,9+/m0/s1
InChIKey
AELCINSCMGFISI-DTWKUNHWSA-N
Cross-matching ID
PubChem CID
19493
ChEBI ID
CHEBI:94631
CAS Number
3721-26-4
DrugBank ID
DB00752
TTD ID
D0H0HJ
ACDINA ID
D00697

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Monoamine oxidase (MAO) TT32XQJ NOUNIPROTAC Inhibitor [2]
Monoamine oxidase type A (MAO-A) TT3WG5C AOFA_HUMAN Inhibitor [8], [9]
Monoamine oxidase type B (MAO-B) TTGP7BY AOFB_HUMAN Inhibitor [9], [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Major depressive disorder
ICD Disease Classification 6A70.3
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Monoamine oxidase type B (MAO-B) DTT MAOB 2.65E-02 1.12E-02 0.07
Monoamine oxidase type A (MAO-A) DTT MAOA 8.14E-01 0.05 0.1
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Tranylcypromine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Sertraline DM0FB1J Major Additive serotonergic effects by the combination of Tranylcypromine and Sertraline. Depression [6A70-6A7Z] [33]
Cyclobenzaprine DM1YBRM Major Additive serotonergic effects by the combination of Tranylcypromine and Cyclobenzaprine. Depression [6A70-6A7Z] [34]
Vilazodone DM4LECQ Major Additive serotonergic effects by the combination of Tranylcypromine and Vilazodone. Depression [6A70-6A7Z] [35]
Nefazodone DM4ZS8M Major Additive serotonergic effects by the combination of Tranylcypromine and Nefazodone. Depression [6A70-6A7Z] [35]
Vortioxetine DM6F1PU Major Additive serotonergic effects by the combination of Tranylcypromine and Vortioxetine. Depression [6A70-6A7Z] [33]
Isocarboxazid DMAF1NB Major Additive hypertensive effects by the combination of Tranylcypromine and Isocarboxazid. Depression [6A70-6A7Z] [36]
Milnacipran DMBFE74 Major Additive serotonergic effects by the combination of Tranylcypromine and Milnacipran. Depression [6A70-6A7Z] [35]
Escitalopram DMFK9HG Major Additive serotonergic effects by the combination of Tranylcypromine and Escitalopram. Depression [6A70-6A7Z] [33]
Desvenlafaxine DMHD4PE Major Additive serotonergic effects by the combination of Tranylcypromine and Desvenlafaxine. Depression [6A70-6A7Z] [35]
Phenelzine DMHIDUE Major Additive hypertensive effects by the combination of Tranylcypromine and Phenelzine. Depression [6A70-6A7Z] [36]
Clomipramine DMINRKW Major Additive serotonergic effects by the combination of Tranylcypromine and Clomipramine. Depression [6A70-6A7Z] [34]
Doxepin DMPI98T Major Additive serotonergic effects by the combination of Tranylcypromine and Doxepin. Depression [6A70-6A7Z] [34]
Maprotiline DMPWB7T Major Additive serotonergic effects by the combination of Tranylcypromine and Maprotiline. Depression [6A70-6A7Z] [34]
Esketamine DMVU687 Major Additive hypertensive effects by the combination of Tranylcypromine and Esketamine. Depression [6A70-6A7Z] [37]
⏷ Show the Full List of 14 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Tranylcypromine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylene blue DMJAPE7 Major Additive serotonergic effects by the combination of Tranylcypromine and Methylene blue. Acquired methaemoglobinaemia [3A93] [34]
Repaglinide DM5SXUV Moderate Increased risk of hypoglycemia by the combination of Tranylcypromine and Repaglinide. Acute diabete complication [5A2Y] [38]
Glibenclamide DM8JXPZ Moderate Increased risk of hypoglycemia by the combination of Tranylcypromine and Glibenclamide. Acute diabete complication [5A2Y] [38]
Tolazamide DMIHRNA Moderate Increased risk of hypoglycemia by the combination of Tranylcypromine and Tolazamide. Acute diabete complication [5A2Y] [39]
Insulin-glulisine DMQI0FU Moderate Increased risk of hypoglycemia by the combination of Tranylcypromine and Insulin-glulisine. Acute diabete complication [5A2Y] [38]
Insulin-aspart DMX7V28 Moderate Increased risk of hypoglycemia by the combination of Tranylcypromine and Insulin-aspart. Acute diabete complication [5A2Y] [40]
Glipizide DMZA5PQ Moderate Increased risk of hypoglycemia by the combination of Tranylcypromine and Glipizide. Acute diabete complication [5A2Y] [38]
Mepyramine DMB4SFH Moderate Additive CNS depression effects by the combination of Tranylcypromine and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [41]
Phenyltoloxamine DMKAEQW Moderate Additive CNS depression effects by the combination of Tranylcypromine and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [41]
Isosorbide dinitrate DMBI4JG Moderate Additive hypotensive effects by the combination of Tranylcypromine and Isosorbide dinitrate. Anal fissure/fistula [DB50] [42]
Trimethaphan DMHF4IQ Moderate Additive hypotensive effects by the combination of Tranylcypromine and Trimethaphan. Aneurysm/dissection [BD50] [43]
Bepridil DM0RKS4 Moderate Additive hypotensive effects by the combination of Tranylcypromine and Bepridil. Angina pectoris [BA40] [43]
Amyl nitrite DMJKO05 Moderate Additive hypotensive effects by the combination of Tranylcypromine and Amyl nitrite. Angina pectoris [BA40] [42]
Nifedipine DMSVOZT Moderate Additive hypotensive effects by the combination of Tranylcypromine and Nifedipine. Angina pectoris [BA40] [42]
Levalbuterol DM5YBO1 Moderate Additive hypertensive effects by the combination of Tranylcypromine and Levalbuterol. Asthma [CA23] [44]
Terbutaline DMD4381 Moderate Additive hypertensive effects by the combination of Tranylcypromine and Terbutaline. Asthma [CA23] [45]
Pirbuterol DMI5678 Moderate Additive hypertensive effects by the combination of Tranylcypromine and Pirbuterol. Asthma [CA23] [44]
Ephedrine DMMV0KW Major Increased risk of hyperpyrexia by the combination of Tranylcypromine and Ephedrine. Asthma [CA23] [42]
Salbutamol DMN9CWF Moderate Additive hypertensive effects by the combination of Tranylcypromine and Salbutamol. Asthma [CA23] [44]
Formoterol DMSOURV Moderate Additive hypertensive effects by the combination of Tranylcypromine and Formoterol. Asthma [CA23] [45]
Lisdexamfetamine DM6W8V5 Major Increased risk of hyperpyrexia by the combination of Tranylcypromine and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [42]
Desipramine DMT2FDC Major Additive serotonergic effects by the combination of Tranylcypromine and Desipramine. Attention deficit hyperactivity disorder [6A05] [34]
Droxidopa DM5YF4M Moderate Additive hypertensive effects by the combination of Tranylcypromine and Droxidopa. Autonomic nervous system disorder [8D87] [46]
Pseudoephedrine DMIVJ0D Major Additive hypertensive effects by the combination of Tranylcypromine and Pseudoephedrine. Breathing abnormality [MD11] [42]
Olodaterol DM62B78 Moderate Additive hypertensive effects by the combination of Tranylcypromine and Olodaterol. Chronic obstructive pulmonary disease [CA22] [45]
Vilanterol DMF5EK1 Moderate Additive hypertensive effects by the combination of Tranylcypromine and Vilanterol. Chronic obstructive pulmonary disease [CA22] [44]
Salmeterol DMIEU69 Moderate Additive hypertensive effects by the combination of Tranylcypromine and Salmeterol. Chronic obstructive pulmonary disease [CA22] [45]
Indacaterol DMQJHR7 Moderate Additive hypertensive effects by the combination of Tranylcypromine and Indacaterol. Chronic obstructive pulmonary disease [CA22] [45]
Levomilnacipran DMV26S8 Major Additive serotonergic effects by the combination of Tranylcypromine and Levomilnacipran. Chronic pain [MG30] [35]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Tranylcypromine and Olopatadine. Conjunctiva disorder [9A60] [47]
Cocaine DMSOX7I Major Additive hypertensive effects by the combination of Tranylcypromine and Cocaine. Corneal disease [9A76-9A78] [48]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Tranylcypromine and Ethanol. Cystitis [GC00] [47]
Cyclandelate DMO0R76 Moderate Additive hypotensive effects by the combination of Tranylcypromine and Cyclandelate. Dementia [6D80-6D8Z] [43]
5-hydroxy-L-tryptophan DMDWZGJ Major Additive serotonergic effects by the combination of Tranylcypromine and 5-hydroxy-L-tryptophan. Discovery agent [N.A.] [49]
LEVONORDEFRIN DMWDJ0H Moderate Additive hypertensive effects by the combination of Tranylcypromine and LEVONORDEFRIN. Discovery agent [N.A.] [50]
Tetrabenazine DMYWQ0O Major Additive hypertensive effects by the combination of Tranylcypromine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [51]
Deutetrabenazine DMUPFLI Major Additive hypertensive effects by the combination of Tranylcypromine and Deutetrabenazine. Dystonic disorder [8A02] [51]
Oxcarbazepine DM5PU6O Major Additive serotonergic effects by the combination of Tranylcypromine and Oxcarbazepine. Epilepsy/seizure [8A61-8A6Z] [34]
Diphenhydramine DMKQTBA Moderate Additive CNS depression effects by the combination of Tranylcypromine and Diphenhydramine. Episodic vestibular syndrome [AB31] [41]
Ethacrynic acid DM60QMR Moderate Additive hypotensive effects by the combination of Tranylcypromine and Ethacrynic acid. Essential hypertension [BA00] [43]
Phenoxybenzamine DM8KSQH Moderate Additive hypotensive effects by the combination of Tranylcypromine and Phenoxybenzamine. Essential hypertension [BA00] [42]
Guanethidine DM9NSWT Moderate Antagonize the effect of Tranylcypromine when combined with Guanethidine. Essential hypertension [BA00] [52]
Mephentermine DMFJH5Q Major Additive hypertensive effects by the combination of Tranylcypromine and Mephentermine. Essential hypertension [BA00] [53]
Oxymetazoline DM8ZXT6 Moderate Decreased metabolism of Tranylcypromine caused by Oxymetazoline mediated inhibition of non-CYP450 enzyme. Eyelid inflammatory disorder [9A02] [54]
Solifenacin DMG592Q Minor Additive anticholinergic effects by the combination of Tranylcypromine and Solifenacin. Functional bladder disorder [GC50] [55]
Propantheline DM2EN6G Minor Additive anticholinergic effects by the combination of Tranylcypromine and Propantheline. Gastric ulcer [DA60] [55]
Dobutamine DMD1B8Z Moderate Additive hypertensive effects by the combination of Tranylcypromine and Dobutamine. Heart failure [BD10-BD1Z] [42]
Nesiritide DMFOIA8 Moderate Additive hypotensive effects by the combination of Tranylcypromine and Nesiritide. Heart failure [BD10-BD1Z] [42]
Chlorothiazide DMLHESP Moderate Additive hypotensive effects by the combination of Tranylcypromine and Chlorothiazide. Heart failure [BD10-BD1Z] [42]
Bumetanide DMRV7H0 Moderate Additive hypotensive effects by the combination of Tranylcypromine and Bumetanide. Heart failure [BD10-BD1Z] [42]
Hydroflumethiazide DMVPUQI Moderate Additive hypotensive effects by the combination of Tranylcypromine and Hydroflumethiazide. Heart failure [BD10-BD1Z] [43]
Tetrahydrozoline DMT57WC Moderate Decreased metabolism of Tranylcypromine caused by Tetrahydrozoline mediated inhibition of non-CYP450 enzyme. Herpes simplex infection [1F00] [54]
Procarbazine DMIK367 Major Additive hypertensive effects by the combination of Tranylcypromine and Procarbazine. Hodgkin lymphoma [2B30] [36]
Maraviroc DMTL94F Moderate Additive hypotensive effects by the combination of Tranylcypromine and Maraviroc. Human immunodeficiency virus disease [1C60-1C62] [42]
Isosorbide mononitrate DMYLMU0 Moderate Additive hypotensive effects by the combination of Tranylcypromine and Isosorbide mononitrate. Hydrocephalus [8D64] [42]
Aliskiren DM1BV7W Moderate Additive hypotensive effects by the combination of Tranylcypromine and Aliskiren. Hypertension [BA00-BA04] [42]
Captopril DM458UM Moderate Additive hypotensive effects by the combination of Tranylcypromine and Captopril. Hypertension [BA00-BA04] [42]
Methyldopa DM5I621 Major Decreased metabolism of Tranylcypromine caused by Methyldopa mediated inhibition of non-CYP450 enzyme. Hypertension [BA00-BA04] [52]
Levamlodipine DM92S6N Moderate Additive hypotensive effects by the combination of Tranylcypromine and Levamlodipine. Hypertension [BA00-BA04] [42]
TAK-491 DMCF6SX Moderate Additive hypotensive effects by the combination of Tranylcypromine and TAK-491. Hypertension [BA00-BA04] [42]
Fenoldopam DMFAOKP Moderate Additive hypotensive effects by the combination of Tranylcypromine and Fenoldopam. Hypertension [BA00-BA04] [42]
Indapamide DMGN1PW Moderate Additive hypotensive effects by the combination of Tranylcypromine and Indapamide. Hypertension [BA00-BA04] [42]
Trichlormethiazide DMHAQCO Moderate Additive hypotensive effects by the combination of Tranylcypromine and Trichlormethiazide. Hypertension [BA00-BA04] [43]
Diazoxide DML1538 Moderate Additive hypotensive effects by the combination of Tranylcypromine and Diazoxide. Hypertension [BA00-BA04] [42]
Perindopril DMOPZDT Moderate Additive hypotensive effects by the combination of Tranylcypromine and Perindopril. Hypertension [BA00-BA04] [42]
Felodipine DMOSW35 Moderate Additive hypotensive effects by the combination of Tranylcypromine and Felodipine. Hypertension [BA00-BA04] [42]
Quinapril DMR8H31 Moderate Additive hypotensive effects by the combination of Tranylcypromine and Quinapril. Hypertension [BA00-BA04] [42]
Deserpidine DMRH7CV Moderate Additive hypertensive effects by the combination of Tranylcypromine and Deserpidine. Hypertension [BA00-BA04] [56]
Telmisartan DMS3GX2 Moderate Additive hypotensive effects by the combination of Tranylcypromine and Telmisartan. Hypertension [BA00-BA04] [42]
Irbesartan DMTP1DC Moderate Additive hypotensive effects by the combination of Tranylcypromine and Irbesartan. Hypertension [BA00-BA04] [42]
Hydrochlorothiazide DMUSZHD Moderate Additive hypotensive effects by the combination of Tranylcypromine and Hydrochlorothiazide. Hypertension [BA00-BA04] [42]
Clevidipine butyrate DMW4M97 Moderate Additive hypotensive effects by the combination of Tranylcypromine and Clevidipine butyrate. Hypertension [BA00-BA04] [42]
Belladonna DM2RBWK Minor Additive anticholinergic effects by the combination of Tranylcypromine and Belladonna. Infectious gastroenteritis/colitis [1A40] [55]
Propiomazine DMKY8V1 Moderate Additive CNS depression effects by the combination of Tranylcypromine and Propiomazine. Insomnia [7A00-7A0Z] [50]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Tranylcypromine and Polyethylene glycol. Irritable bowel syndrome [DD91] [57]
Dicyclomine DMZSDGX Minor Additive anticholinergic effects by the combination of Tranylcypromine and Dicyclomine. Irritable bowel syndrome [DD91] [55]
Naphazoline DMJFZDL Moderate Decreased metabolism of Tranylcypromine caused by Naphazoline mediated inhibition of non-CYP450 enzyme. Itching [1F28-1G07] [54]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Tranylcypromine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [58]
Almogran DM7I64Z Major Additive serotonergic effects by the combination of Tranylcypromine and Almogran. Migraine [8A80] [59]
Frovatriptan DM7RE8P Major Additive serotonergic effects by the combination of Tranylcypromine and Frovatriptan. Migraine [8A80] [59]
Rizatriptan DMDJMA3 Major Decreased metabolism of Tranylcypromine caused by Rizatriptan mediated inhibition of non-CYP450 enzyme. Migraine [8A80] [59]
Naratriptan DMO50U2 Major Additive serotonergic effects by the combination of Tranylcypromine and Naratriptan. Migraine [8A80] [59]
Lasmiditan DMXLVDT Major Additive serotonergic effects by the combination of Tranylcypromine and Lasmiditan. Migraine [8A80] [35]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Tranylcypromine and Flibanserin. Mood disorder [6A60-6E23] [60]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Tranylcypromine and Thalidomide. Multiple myeloma [2A83] [47]
Ozanimod DMT6AM2 Major Decreased metabolism of Tranylcypromine caused by Ozanimod mediated inhibition of non-CYP450 enzyme. Multiple sclerosis [8A40] [61]
Dextroamphetamine DMMIHVP Major Increased risk of hyperpyrexia by the combination of Tranylcypromine and Dextroamphetamine. Narcolepsy [7A20] [42]
Phenindamine DMDTC7R Moderate Additive CNS depression effects by the combination of Tranylcypromine and Phenindamine. Nasopharyngitis [CA00] [41]
Dimenhydrinate DM264B3 Minor Additive anticholinergic effects by the combination of Tranylcypromine and Dimenhydrinate. Nausea/vomiting [MD90] [55]
Promethazine DM6I5GR Moderate Additive hypotensive effects by the combination of Tranylcypromine and Promethazine. Nausea/vomiting [MD90] [42]
Cyclizine DM9G7BS Moderate Additive CNS depression effects by the combination of Tranylcypromine and Cyclizine. Nausea/vomiting [MD90] [41]
Metoclopramide DMFA5MY Moderate Increased risk of hyperpyrexia by the combination of Tranylcypromine and Metoclopramide. Nausea/vomiting [MD90] [62]
Granisetron DMIUW25 Major Additive serotonergic effects by the combination of Tranylcypromine and Granisetron. Nausea/vomiting [MD90] [41]
Dolasetron DMMG26Z Major Additive serotonergic effects by the combination of Tranylcypromine and Dolasetron. Nausea/vomiting [MD90] [41]
Ondansetron DMOTQ1I Major Additive serotonergic effects by the combination of Tranylcypromine and Ondansetron. Nausea/vomiting [MD90] [41]
Bupropion DM5PCS7 Major Additive hypertensive effects by the combination of Tranylcypromine and Bupropion. Nicotine use disorder [6C4A] [63]
Phendimetrazine DM6TS1N Major Increased risk of hyperpyrexia by the combination of Tranylcypromine and Phendimetrazine. Obesity [5B80-5B81] [42]
Amfepramone DM9YSNQ Major Increased risk of hyperpyrexia by the combination of Tranylcypromine and Amfepramone. Obesity [5B80-5B81] [42]
Sibutramine DMFJTDI Major Additive serotonergic effects by the combination of Tranylcypromine and Sibutramine. Obesity [5B80-5B81] [49]
Lorcaserin DMG6OYJ Major Additive serotonergic effects by the combination of Tranylcypromine and Lorcaserin. Obesity [5B80-5B81] [64]
Benzphetamine DMIJATC Major Increased risk of hyperpyrexia by the combination of Tranylcypromine and Benzphetamine. Obesity [5B80-5B81] [42]
Dexfenfluramine DMJ7YDS Major Additive serotonergic effects by the combination of Tranylcypromine and Dexfenfluramine. Obesity [5B80-5B81] [49]
Propylhexedrine DMTBW2O Moderate Decreased metabolism of Tranylcypromine caused by Propylhexedrine mediated inhibition of non-CYP450 enzyme. Obesity [5B80-5B81] [54]
Polythiazide DMCH80F Moderate Additive hypotensive effects by the combination of Tranylcypromine and Polythiazide. Oedema [MG29] [43]
Lofexidine DM1WXA6 Moderate Additive hypotensive effects by the combination of Tranylcypromine and Lofexidine. Opioid use disorder [6C43] [42]
Apraclonidine DMO4PVE Major Additive hypertensive effects by the combination of Tranylcypromine and Apraclonidine. Optic nerve disorder [9C40] [63]
Methamphetamine DMPM4SK Major Additive hypertensive effects by the combination of Tranylcypromine and Methamphetamine. Pain [MG30-MG3Z] [65]
Biperiden DME78OA Minor Additive anticholinergic effects by the combination of Tranylcypromine and Biperiden. Parkinsonism [8A00] [66]
Levodopa DMN3E57 Major Additive hypertensive effects by the combination of Tranylcypromine and Levodopa. Parkinsonism [8A00] [42]
Dopamine DMPGUCF Major Increased risk of hyperpyrexia by the combination of Tranylcypromine and Dopamine. Parkinsonism [8A00] [42]
Ritodrine DM4V6RL Moderate Additive hypertensive effects by the combination of Tranylcypromine and Ritodrine. Preterm labour/delivery [JB00] [44]
Terazosin DM3JCVS Moderate Additive hypotensive effects by the combination of Tranylcypromine and Terazosin. Prostate hyperplasia [GA90] [42]
Silodosin DMJSBT6 Moderate Additive hypotensive effects by the combination of Tranylcypromine and Silodosin. Prostate hyperplasia [GA90] [42]
Levomepromazine DMIKFEL Moderate Additive hypotensive effects by the combination of Tranylcypromine and Levomepromazine. Psychotic disorder [6A20-6A25] [50]
Selexipag DMAHSU0 Moderate Additive hypotensive effects by the combination of Tranylcypromine and Selexipag. Pulmonary hypertension [BB01] [42]
Tolazoline DMI40NL Moderate Additive hypotensive effects by the combination of Tranylcypromine and Tolazoline. Pulmonary hypertension [BB01] [43]
Epoprostenol DMUTYR2 Moderate Additive hypotensive effects by the combination of Tranylcypromine and Epoprostenol. Pulmonary hypertension [BB01] [42]
Iloprost DMVPZBE Moderate Additive hypotensive effects by the combination of Tranylcypromine and Iloprost. Pulmonary hypertension [BB01] [42]
Mesoridazine DM2ZGAN Moderate Additive CNS depression effects by the combination of Tranylcypromine and Mesoridazine. Schizophrenia [6A20] [50]
Trifluoperazine DMKBYWI Moderate Additive hypotensive effects by the combination of Tranylcypromine and Trifluoperazine. Schizophrenia [6A20] [42]
Fentanyl DM8WAHT Major Additive serotonergic effects by the combination of Tranylcypromine and Fentanyl. Sensation disturbance [MB40] [67]
Avanafil DM75CXN Moderate Additive hypotensive effects by the combination of Tranylcypromine and Avanafil. Sexual dysfunction [HA00-HA01] [42]
Tadalafil DMJZHT1 Moderate Additive hypotensive effects by the combination of Tranylcypromine and Tadalafil. Sexual dysfunction [HA00-HA01] [42]
Vardenafil DMTBGW8 Moderate Additive hypotensive effects by the combination of Tranylcypromine and Vardenafil. Sexual dysfunction [HA00-HA01] [42]
Papaverine DMCA9QP Moderate Additive hypotensive effects by the combination of Tranylcypromine and Papaverine. Tonus and reflex abnormality [MB47] [42]
Tolbutamide DM02AWV Moderate Increased risk of hypoglycemia by the combination of Tranylcypromine and Tolbutamide. Type 2 diabetes mellitus [5A11] [39]
Insulin-detemir DMOA4VW Moderate Increased risk of hypoglycemia by the combination of Tranylcypromine and Insulin-detemir. Type-1/2 diabete [5A10-5A11] [38]
Insulin degludec DMPL395 Moderate Increased risk of hypoglycemia by the combination of Tranylcypromine and Insulin degludec. Type-1/2 diabete [5A10-5A11] [38]
Chlorpheniramine DM5URA2 Moderate Additive CNS depression effects by the combination of Tranylcypromine and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [41]
Methdilazine DMAUHQX Moderate Additive hypotensive effects by the combination of Tranylcypromine and Methdilazine. Vasomotor/allergic rhinitis [CA08] [50]
Trimeprazine DMEMV9D Moderate Additive CNS depression effects by the combination of Tranylcypromine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [50]
Brompheniramine DMFOVSD Moderate Additive CNS depression effects by the combination of Tranylcypromine and Brompheniramine. Vasomotor/allergic rhinitis [CA08] [41]
Xylometazoline DMKV32D Moderate Decreased metabolism of Tranylcypromine caused by Xylometazoline mediated inhibition of non-CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [54]
Acrivastine DMTIGA0 Moderate Additive CNS depression effects by the combination of Tranylcypromine and Acrivastine. Vasomotor/allergic rhinitis [CA08] [41]
⏷ Show the Full List of 134 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Kyselina citronova E00014 311 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Sunset yellow FCF E00255 17730 Colorant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite E00392 104805 Diluent
Calcium sulfate anhydrous E00303 24497 Desiccant; Diluent
Carboxymethylcellulose sodium E00621 Not Available Adsorbent; Binding agent; Disintegrant; Emulsifying agent; Suspending agent; Viscosity-controlling agent
Carmellose sodium E00625 Not Available Disintegrant
Citric acid monohydrate E00271 22230 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Gelatin E00630 Not Available Other agent
Hypromellose E00634 Not Available Coating agent
Lithol rubin BCA E00607 135423095 Colorant
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
⏷ Show the Full List of 22 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Tranylcypromine 10 mg tablet 10 mg Oral Tablet Oral
Tranylcypromine Sulfate 10mg tablet 10mg Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
8 Tramadol and another atypical opioid meperidine have exaggerated serotonin syndrome behavioural effects, but decreased analgesic effects, in genetically deficient serotonin transporter (SERT) mice. Int J Neuropsychopharmacol. 2009 Mar 11:1-11.
9 Tranylcypromine: new perspectives on an "old" drug. Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):268-73.
10 Dopamine D2 receptors: a potential pharmacological target for nomifensine and tranylcypromine but not other antidepressant treatments. Pharmacol Biochem Behav. 1995 Aug;51(4):565-9.
11 Photoluminescence of CdTe nanocrystals modulated by methylene blue and DNA. A label-free luminescent signaling nanohybrid platform. Phys Chem Chem Phys. 2009 Jul 7;11(25):5062-9.
12 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
13 LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
14 Emerging drugs for Parkinson's disease. Expert Opin Emerg Drugs. 2006 Sep;11(3):403-17.
15 Limitation of adipose tissue enlargement in rats chronically treated with semicarbazide-sensitive amine oxidase and monoamine oxidase inhibitors. Pharmacol Res. 2008 Jun;57(6):426-34.
16 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490).
17 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
18 Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res. 2009 Aug;16(2):148-59.
19 Novel monoamine oxidase inhibitors, 3-(2-aminoethoxy)-1,2-benzisoxazole derivatives, and their differential reversibility. Jpn J Pharmacol. 2002 Feb;88(2):174-82.
20 Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells. Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H821-8.
21 Multiple mechanisms of action: the pharmacological profile of budipine. J Neural Transm Suppl. 1999;56:83-105.
22 Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.
23 Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. Hum Psychopharmacol. 2002 Dec;17(8):401-5.
24 Further investigation into the mechanism of tachykinin NK(2) receptor-triggered serotonin release from guinea-pig proximal colon. J Pharmacol Sci. 2009 May;110(1):122-6.
25 MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995 May;12(3):185-219.
26 Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
27 Inhibition of rat brain monoamine oxidase activities by psoralen and isopsoralen: implications for the treatment of affective disorders. Pharmacol Toxicol. 2001 Feb;88(2):75-80.
28 Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
29 Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets. 2012 Apr;13(4):483-94.
30 Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157. Neuropsychopharmacology. 2010 Feb;35(3):623-31.
31 Proposed structural basis of interaction of piperine and related compounds with monoamine oxidases. Bioorg Med Chem Lett. 2010 Jan 15;20(2):537-40.
32 Phase I clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: tolerance and pharmacokinetics study of escalating single oral doses. Methods Find Exp Clin Pharmacol. 2008 Mar;30(2):141-7.
33 Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL "Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings." J Clin Psychopharmacol 13 (1993): 312-20. [PMID: 8227489]
34 Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
35 Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
36 Bazire SR "Sudden death associated with switching monoamine oxidase inhibitors." Drug Intell Clin Pharm 20 (1986): 954-6. [PMID: 3816543]
37 Cerner Multum, Inc. "Australian Product Information.".
38 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
39 Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301. [PMID: 14071924]
40 Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
41 Canadian Pharmacists Association.
42 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
43 Product Information. Marplan (isocarboxazid) Roche Laboratories, Nutley, NJ.
44 Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5. [PMID: 4685619]
45 Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology. J Allergy Clin Immunol 75 (1985): 443-9. [PMID: 2858503]
46 Product Information. Northera (droxidopa). Chelsea Therapeutics Inc, Charlotte, NC.
47 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
48 Product Information. Cocaine Hydrochloride Nasal (cocaine nasal). Genus Lifesciences Inc., Allentown, PA.
49 Graber MA, Hoehns TB, Perry PJ "Sertraline-phenelzine drug interaction: a serotonin syndrome reaction." Ann Pharmacother 28 (1994): 732-5. [PMID: 7919561]
50 Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62. [PMID: 14197995]
51 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
52 Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31. [PMID: 8845455]
53 Davies B, Bannister R, Sever P "Pressor amines and monoamine-oxidase inhibitors for treatment of postural hypotension in autonomic failure: limitations and hazards." Lancet 1 (1978): 172-5. [PMID: 74603]
54 Cusson JR, Goldenberg E, Larochelle P "Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans." J Clin Pharmacol 31 (1991): 462-7. [PMID: 2050833]
55 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
56 Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7. [PMID: 5655478]
57 Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
58 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
59 Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
60 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
61 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
62 Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984): 548-9. [PMID: 6541544]
63 De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5. [PMID: 4379192]
64 Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
65 Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5. [PMID: 4685619]
66 Product Information. Artane (trihexyphenidyl). Lederle Laboratories, Wayne, NJ.
67 Browne B, Linter S "Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment." Br J Psychiatry 151 (1987): 210-2. [PMID: 2891392]